Myasthenia Gravis Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight

DelveInsight's, "Myasthenia Gravis Pipeline Insight 2026" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Myasthenia Gravis Pipeline? Click here to explore the therapies and trials making headlines @ [https://www.delveinsight.com/sample-request/myasthenia-gravis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Myasthenia Gravis Pipeline Report

* On February 19, 2026- Alexion Pharmaceuticals, Inc . initiated a phase 3, Open-label, Single-arm, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants (6 to < 18 Years of Age) With Generalized Myasthenia Gravis (gMG).
* On February 18, 2026- argenx announced a trial is to investigate the PK, PD, safety, and activity of efgartigimod IV in children and adolescents aged from 2 to less than 18 years of age with gMG.
* On February 17, 2026- Immunovant Sciences GmbH conducted a phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of IMVT-1402 in Patients With Mild to Severe Generalized Myasthenia Gravis.
* On February 17, 2026- Vor Biopharma initiated a Phase 3 study with an open-label extension (OLE) to evaluate the efficacy and safety of telitacicept in a global patient population with gMG. The total duration of the study is variable but will include an approximately 4-week screening period, a 24-week double-blind treatment period (Week 0 through Week 24), a 48-week OLE (Week 24 through Week 72), followed by an extended OLE period (E-OLE), and an 8-week end-of-study follow-up period. The E-OLE is variable duration, defined as the period after the 48-week OLE period until telitacicept is approved for MG in the country or the further development in the indication is concluded.
* On February 17, 2026- Janssen Research & Development LLC announced a study is to determine the effect of nipocalimab on total serum immunoglobulin G (IgG) in pediatric participants 2 to less than (



This release was published on openPR.